Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Convection Enhanced Delivery (CED) of IL13-PE38QQR Infusion After Resection Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Supratentorial Malignant Glioma

NCT00089427 is registered in ClinicalTrials.gov with INSYS Therapeutics Inc as lead sponsor.

NCT NCT00089427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00089427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Convection Enhanced Delivery (CED) of IL13-PE38QQR Infusion After Resection Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Supratentorial Malignant Glioma
Lead sponsor
INSYS Therapeutics Inc
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2004
Completion date
Not reported
Enrollment
24
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, glioblastoma multiforme, oligoastrocytoma